Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype

Palata, Ondřej; Hradilova, Nada; Myšíková, D.; Kutna, Beata; Mrazkova, Hana; Lischke, Robert; Špíšek, Radek; Adkins, Irena

doi:10.1016/j.imlet.2020.01.001

Cited by 16 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the researchers showed that all but one of the genes are regulated by genomic methylation, and not all of them are co-expressed [ 307 ]. In 2020, the team of Palat et al conducted research in which 12 selected cancer antigens were determined (CEA, MAGE-A1, MAGE-A3, MAGE-A4, PRAME, hTERT, HER2, MUC1, Survivin, STEAP1, SOX2 and NY-ESO-1), and their involvement in the pathogenesis of lung cancer was studied, with a particular emphasis on NSCLC subtypes [ 308 ]. Based on the analyses carried out, the researchers showed a higher expression of TAA SCCs in relation to ACs.…”

Section: Resultsmentioning

confidence: 99%

“…In addition, they showed that the patients’ T-cell response to stimulation was significantly lower in patients with SCCs than those with ACs. Researchers have suggested that there are specific differences in T-cell function between NSCLC subtypes [ 308 ]. Some researchers have pointed out that cancer proteins circulating in serum or plasma, released from cancer cells, are few and their sensitivity, especially in terms of diagnostics, is low, especially in the early stages of cancer.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer

Smok-Kalwat

Mertowska

Mertowski

et al. 2023

IJMS

View full text Add to dashboard Cite

Lung cancer is a disease that in recent years has become one of the greatest threats to modern society. Every year there are more and more new cases and the percentage of deaths caused by this type of cancer increases. Despite many studies, scientists are still looking for answers regarding the mechanisms of lung cancer development and progression, with particular emphasis on the role of the immune system. The aim of this literature review was to present the importance of disorders of the immune system and the accompanying changes at the level of cell signaling in the pathogenesis of lung cancer. The collected results showed that in the process of immunopathogenesis of almost all subtypes of lung cancer, changes in the tumor microenvironment, deregulation of immune checkpoints and abnormalities in cell signaling pathways are involved, which contribute to the multistage and multifaceted carcinogenesis of this type of cancer. We, therefore, suggest that in future studies, researchers should focus on a detailed analysis of tumor microenvironmental immune checkpoints, and to validate their validity, perform genetic polymorphism analyses in a wide range of patients and healthy individuals to determine the genetic susceptibility to lung cancer development. In addition, further research related to the analysis of the tumor microenvironment; immune system disorders, with a particular emphasis on immunological checkpoints and genetic differences may contribute to the development of new personalized therapies that improve the prognosis of patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer

Smok-Kalwat

Mertowska

Mertowski

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Until now, very few reports have described the expansion of antigen-specific T cells in lung cancer patients [40,41]. In a study by Groeper et al, the authors cultured tumorinfiltrating lymphocytes (TIL) from 33 stage I-III patients with autologous DCs and monitored the expansion of T cells specific to MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, Multi-MAGE, and NY-ESO-1 [41].…”

Section: Discussionmentioning

confidence: 99%

A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients

Hannani¹,

Leplus²,

Laurin

et al. 2023

IJMS

View full text Add to dashboard Cite

The purpose of immune checkpoint inhibitor (ICI)-based therapies is to help the patient’s immune system to combat tumors by restoring the immune response mediated by CD8+ cytotoxic T cells. Despite impressive clinical responses, most patients do not respond to ICIs. Therapeutic vaccines with autologous professional antigen-presenting cells, including dendritic cells, do not show yet significant clinical benefit. To improve these approaches, we have developed a new therapeutic vaccine based on an allogeneic plasmacytoid dendritic cell line (PDC*line), which efficiently activates the CD8+ T-cell response in the context of melanoma. The goal of the study is to demonstrate the potential of this platform to activate circulating tumor-specific CD8+ T cells in patients with lung cancer, specifically non-small-cell lung cancer (NSCLC). PDC*line cells loaded with peptides derived from tumor antigens are used to stimulate the peripheral blood mononuclear cells of NSCLC patients. Very interestingly, we demonstrate an efficient activation of specific T cells for at least two tumor antigens in 69% of patients irrespective of tumor antigen mRNA overexpression and NSCLC subtype. We also show, for the first time, that the antitumor CD8+ T-cell expansion is considerably improved by clinical-grade anti-PD-1 antibodies. Using PDC*line cells as an antigen presentation platform, we show that circulating antitumor CD8+ T cells from lung cancer patients can be activated, and we demonstrate the synergistic effect of anti-PD-1 on this expansion. These results are encouraging for the development of a PDC*line-based vaccine in NSCLC patients, especially in combination with ICIs.

show abstract

“…These disparate results might be due to the different genomic compositions of tumors or the different immune microenvironments between different tumor types. In addition, since cancer-testis antigens can induce specific cellular and humoral immune responses, there are currently two different strategies for using cancer-testis antigens as tumor immunotherapy targets: one is to directly enhance cancer-testis antigen-specific T lymphocytes, known as adoptive T-cell therapies ( Xia et al, 2018 ; Zhang and Wang, 2019 ), and the other is to introduce other cancer-testis antigens to promote immune recognition and enhance anti-tumor immune responses ( Dreno et al, 2018 ; Palata et al, 2020 ). Although this study showed some associations between MMS22L and immune cell infiltration, it still seemed insufficient to explain the direct impact of MMS22L on immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Integrative pan-cancer landscape of MMS22L and its potential role in hepatocellular carcinoma

2022

View full text Add to dashboard Cite

Methyl methanesulfonate-sensitivity protein 22-like (MMS22L) is crucial in protecting genome integrity during DNA replication by preventing DNA damage and maintaining efficient homologous recombination. However, the role of MMS22L in human cancers remains unclear. Here, we reported the landscape of MMS22L using multi-omics data and identified the relationship between the MMS22L status and pan-cancer prognosis. In addition, the correlation of MMS22L mRNA expression levels with tumor mutational burden, microsatellite instability, homologous recombination deficiency, and loss of heterozygosity in pan-cancer was also described in this study. Furthermore, this study was the first to characterize the relationship between mRNA expression of MMS22L and immune cell infiltration in the tumor microenvironment in human cancer. Concurrently, this study explored the crucial role of MMS22L in different immunotherapy cohorts through current immunotherapy experiments. Eventually, we investigated the role of MMS22L in hepatocellular carcinoma (HCC). The results demonstrated that MMS22L is widely expressed in multiple HCC cell lines, and our results emphasized that MMS22L was involved in HCC progression and affects the prognosis of patients with HCC through multiple independent validation cohorts. Collectively, our findings reveal the essential role of MMS22L as a tumor-regulating gene in human cancers while further emphasizing its feasibility as a novel molecular marker in HCC. These findings provide an essential reference for the study of MMS22L in tumors.

show abstract

Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype

Cited by 16 publications

References 32 publications

The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer

The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer

A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients

Integrative pan-cancer landscape of MMS22L and its potential role in hepatocellular carcinoma

Contact Info

Product

Resources

About